Dave Singh

Dave Singh

University Of Manchester, Manchester University Nhs Foundation Trust, Manchester, Uk.

Direct Impact

Concepts for which Dave Singh has direct influence:

safety tolerability
ax-8 tablets
glycopyrronium bromide
chadox1 hbv
single ascending
tpi asm8
multicentre phase

External impact

Concepts related to the work of other authors for which Dave Singh has influence:

physical activity
early copd
humanized monoclonal antibody
cigarette smokers
chronic pulmonary
sch 55700
composite endpoint

Prominent publications by Dave Singh

KOL-Index: 163 Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: "young" individuals with COPD and ...
Known for
Young Chronic | Persistent Airflow Limitation | 20-50 | Exacerbations
KOL-Index: 144 AIMS: Inhaled nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale that warrants urgent investigation of its therapeutic potential in patients with COVID-19. UFH has antiviral effects and prevents the SARS-CoV-2 virus' entry into mammalian cells. In addition, UFH has significant anti-inflammatory and anticoagulant properties, which limit progression of lung ...
Known for
On-Going Trials | Intention-To-Treat Principle | Inhale-Hep Metatrial | Unfractionated
KOL-Index: 40 Inhaled corticosteroids do not suppress inflammation or control symptoms in all asthmatics. In particular, corticosteroid insensitivity exists in many patients and may potentially be reversible. There is a need to develop new anti-inflammatory therapies for this disease. This article critically reviews clinical trial data of novel anti-inflammatory drugs in asthma, encompassing specific ...
Known for
Drugs Asthma | Inflammatory Therapies
KOL-Index: 30 The EvA study is a European Union-funded project under the Seventh Framework Programme (FP7), which aims at defining new markers for chronic obstructive pulmonary disease (COPD) and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and ...
Known for
Define Phenotypes | Expression Markers | Airway Project | Eva Aims
KOL-Index: 26 Inhaled nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale that warrants urgent investigation of its therapeutic potential in patients with COVID-19. UFH has antiviral effects and prevents the SARS-CoV-2 virus’ entry into mammalian cells. In addition, UFH has significant anti-inflammatory and anti-coagulant properties, which limit progression of lung ...
Known for
Relevant Ethics Committee | Contributing | Worsening | Inhale-Hep Meta-Trial
KOL-Index: 21 EvA (Emphysema versus Airway disease) is a multicentre project to study mechanisms and identify biomarkers of emphysema and airway disease in chronic obstructive pulmonary disease (COPD). The objective of this study was to delineate objectively imaging-based emphysema-dominant and airway disease-dominant phenotypes using quantitative computed tomography (QCT) indices, standardised with a ...
Known for
Higher Lung Volumes | Po2 | Scanner | Airway Wall Geometry
KOL-Index: 14 BACKGROUND: Changes in microbial community composition in the lung of patients suffering from moderate to severe COPD have been well documented. However, knowledge about specific microbiome structures in the human lung associated with CT defined abnormalities is limited. METHODS: Bacterial community composition derived from brush samples from lungs of 16 patients suffering from different CT ...
Known for
Brush | 16s Rrna Gene Fragment | Subtypes Community | Microbial Communities

University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172